Cited by 43Mitochondrial Function and PathologyParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Mitochondrial medicine and the neurodegenerative mitochondriopathies

Open access
Swerdlow, Russell H.·2009·Pharmaceuticals

Abstract

Neurodegenerative diseases are a common late-life scourge for which disease-modifying treatments are sorely needed. Mitochondrial perturbation is commonly observed in these diseases, so pursuing treatment development strategies that target mitochondria or processes affected by mitochondria seems reasonable. This review discusses the rationale underlying past and current efforts to treat neurodegenerative diseases using mitochondrial medicine, and tries to predict how future efforts might proceed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph2030150

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Swerdlow, R. H.
Affiliations
University of Kansas (US)
Corresponding author
Swerdlow, Russell H.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2009-12-03
Volume
2
Issue
3
Pages
150-167
ISSN
1424-8247 (ISSN-L)
OpenAlex
W1988248211
Cited by
43
References
111
Citations by year
2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 7 · 2012: 3
FWCI
0.94
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute on Aging (R01AG022407)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
mitochondrial medicine, neurodegenerative diseases, mitochondrial disease, mitochondrial dysfunction, disease-modifying therapy, mitochondrial-targeted therapy, treatment development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review